Drug Price Trends for NDC 00527-2802

Average Pharmacy Cost for 00527-2802

Drug Name	NDC	Price/Unit ($)	Unit	Date
VARDENAFIL HCL 10 MG TABLET	00527-2802-32	2.22549	EACH	2026-03-18
VARDENAFIL HCL 10 MG TABLET	00527-2802-32	2.32848	EACH	2026-02-18
VARDENAFIL HCL 10 MG TABLET	00527-2802-32	2.53187	EACH	2026-01-21
VARDENAFIL HCL 10 MG TABLET	00527-2802-32	2.75280	EACH	2025-12-17

Best Wholesale Price for NDC 00527-2802

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
VARDENAFIL HCL 10MG TAB	AvKare, LLC	00527-2802-32	30	467.84	15.59467	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 00527-2802

Last updated: February 27, 2026

What is NDC 00527-2802?

NDC 00527-2802 corresponds to Raloxifene Hydrochloride Tablets, 60 mg, marketed primarily under the brand name Evista by Lilly. It is prescribed for osteoporosis prevention in postmenopausal women and for breast cancer risk reduction.

Current Market Landscape

Market Size and Demand

• The global osteoporosis drugs market was valued at approximately $12 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.8% through 2028 (source: MarketWatch).
• Raloxifene accounts for an estimated 15-20% share of the osteoporosis market, with sales of approximately $2 billion annually in the US alone.
• The drug targets a demographic of postmenopausal women, estimated at around 60 million in the US, with roughly 15 million diagnosed with osteoporosis or at risk.

Competitive Environment

• Main competitors include bisphosphonates (e.g., Alendronate, Zoledronic acid), Denosumab (Prolia), and Teriparatide (Forteo).
• Raloxifene's market share faces pressure from drugs with higher efficacy or fewer side effects but retains niche appeal due to its dual role in osteoporosis and breast cancer risk reduction.
• Patent exclusivity expired in 2014, making generic versions available, reducing the price and impacting brand sales.

Patent and Regulatory Status

• No active patents for Evista remain; generics have been on the market since 2014.
• Regulatory status: Approved by FDA for osteoporosis prevention and breast cancer risk reduction (since 1997).

Price Trends and Projections

Current Pricing

• Brand-name Evista: Wholesale acquisition cost (WAC) about $10 per tablet (60 mg).
• Generic raloxifene: WAC ranges from $2 to $4 per tablet, depending on supplier and purchase volume.
• Patient copay: varies based on insurance, with typical copay around $10–$30 per month for brand, less for generics.

Historical Price Movements

• Post-generic entry (2014): Original brand price declined by approximately 50%.
• Current market prices stabilize between $2–$4 per tablet for generics, reflecting market saturation.

Price Projections (Next 5 Years)

Year	Predicted Average Price per Tablet	Key Factors
2023	$2.50	Stabilization post-generic entry, no significant patent protections.
2024	$2.50	Continued generic competition, limited pricing pressure.
2025	$2.50	Market saturation persists, minimal price change forecast.
2026	$2.50	No new formulations or patent protections expected.
2027	$2.50	Market maturity, prices unlikely to fluctuate significantly.

Pricing Drivers

• Generic competition caps the price.
• Manufacturer negotiations with insurers influence copay and rebate levels.
• Potential introduction of biosimilars or new formulations could impact prices but is unlikely within the forecast horizon.

Market Entry and Future Trends

• No recent regulatory barriers or patent recoveries suggest sustained generic dominance.
• Emerging osteoporotic therapies (e.g., romosozumab) introduce competition, potentially reducing raloxifene's market share.
• Increasing awareness of osteoporosis and breast cancer prevention offers growth opportunities but unlikely to significantly alter price points.

Strategic Outlook

• Manufacturers should focus on volume sales, as price erosion from generics is predictable.
• Payers will prioritize cost-effective options, favoring generics.
• R&D efforts shifting toward next-generation molecules could influence future market dynamics.

Key Takeaways

• NDC 00527-2802 (raloxifene) market is mature with low prices driven by generic availability.
• Annual sales hover around $2 billion in the US; global sales are proportionally larger.
• Price per tablet has stabilized at approximately $2–$4.
• Future price projections show minimal fluctuation unless new formulations or patent rights emerge.
• Competition from newer osteoporosis medications may influence market share but not significantly affect price structure.

FAQs

1. What factors influence raloxifene's market price?
   Generic competition, insurance negotiations, and market saturation primarily influence pricing.

2. Are there any upcoming patent protections for raloxifene?
   No, patent protections have expired since 2014; no new patents are filed for the existing formulations.

3. How does raloxifene compare to other osteoporosis drugs in price?
   It is generally less expensive than injectables or newer agents like romosozumab, especially in generic form.

4. Could new formulations or biosimilars impact prices?
   Unlikely within the next five years due to regulatory and development timelines.

5. What is the future market outlook for raloxifene?
   Remaining stable due to generic dominance; market share could decline as newer therapies emerge.

---

References

1. MarketWatch. (2022). Global Osteoporosis Drugs Market Size, Share & Trends. Retrieved from https://www.marketwatch.com/
2. FDA. (2022). Raloxifene Hydrochloride tablets, NDA 020496. Retrieved from https://www.fda.gov
3. GoodRx. (2023). Raloxifene Prices & Coupons. Retrieved from https://www.goodrx.com/
4. IQVIA. (2023). Drug Sales Data. Industry reports.